Casdin Capital’s Prime Medicine PRME Stock Holding History

Casdin Capital’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7M	Hold	3,167,175	–	–	0.59%	26
2026 Q1	$11M	Hold	3,167,175	–	–	0.83%	23
2025 Q4	$11M	Hold	3,167,175	–	–	0.68%	25
2025 Q3	$17.5M	Buy	3,167,175 +1,600,000	+102%	+$6.5M	1.46%	14
2025 Q2	$3.87M	Buy	1,567,175 +1,200,000	+327%	+$1.85M	0.35%	24
2025 Q1	$731K	Hold	367,175	–	–	0.06%	40
2024 Q4	$1.07M	Hold	367,175	–	–	0.07%	36
2024 Q3	$1.42M	Hold	367,175	–	–	0.09%	31
2024 Q2	$1.89M	Hold	367,175	–	–	0.14%	31
2024 Q1	$2.57M	Hold	367,175	–	–	0.19%	32
2023 Q4	$3.25M	Hold	367,175	–	–	0.32%	30
2023 Q3	$3.5M	Hold	367,175	–	–	0.39%	29
2023 Q2	$5.38M	Sell	367,175 -367,175	-50%	-$5.13M	0.47%	28
2023 Q1	$9.03M	Hold	734,350	–	–	0.74%	30
2022 Q4	$13.6M	Buy	+734,350	New	+$13.3M	1.06%	27

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Casdin Capital's PRME Position: Q2 2026 in Review

Casdin Capital held its Prime Medicine (PRME) position steady in Q2 2026 at 3,167,175 shares worth $11.7M. The position accounts for 0.59% of the portfolio, ranked #26.

Casdin Capital first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $17.5M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

Casdin Capital held 3,167,175 shares of Prime Medicine worth $11.7M as of Q2 2026.
Casdin Capital left its Prime Medicine share count unchanged in Q2 2026.
Prime Medicine made up 0.59% of Casdin Capital's portfolio in Q2 2026, its #26 holding.
Casdin Capital first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
Casdin Capital's Prime Medicine position peaked at $17.5M in Q3 2025.
187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.